ライフサイエンスコーパス: occult blood

1 (EPO) levels, and stool and urine tests for occult blood.

2 t were processed for the evaluation of fecal occult blood.

3 nced neoplasia had a positive test for fecal occult blood.

4 for fecal leukocytes nor an assay for fecal occult blood, alone or in combination, allowed for the r

5 nnual treatment reduced prevalence of faecal occult blood and 80 mg/kg dose reduced prevalence of fae

6 Both annual testing for fecal occult blood and biennial testing significantly reduce m

7 Participants who tested positive for faecal occult blood and who were eligible for and considered fi

8 aining in and on the HVE tube was tested for occult blood by the guiac resin method.

9 ts provided a stool specimen for culture and occult blood by the standard methods.

10 d EAEC in DNA extracted from stools and from occult blood cards.

11 dition to currently available methods (fecal occult blood, flexible sigmoidoscopy, colonoscopy, and d

12 for colorectal cancer recommend annual fecal occult blood (FOB) testing for adults aged 50 years and

13 There is growing evidence that faecal-occult-blood (FOB) screening may reduce colorectal cance

14 patients who received the stool testing for occult blood (FOBT).

15 Patients with faecal occult blood, haematochezia, iron-deficiency anaemia, or

16 cult II, a widely used guaiac test for fecal occult blood, has a low sensitivity for detecting colore

17 Using occult blood home test kits, we found overall 90% agreem

18 The predictive value of immunological fecal occult blood (iFOB) testing for the screening of colorec

19 cal cards that was used for the detection of occult blood is of use in identifying diarrheagenic E. c

20 this effect results from possible increased occult blood loss and a cytokine-mediated effect on SF i

21 tric ulcers, and a higher incidence of fecal occult blood loss.

22 Fecal tests (occult blood, methylation) engender excellent patient co

23 e = 3,520; IRR = 0.87 (0.80-0.96) and Faecal Occult Blood Number eligible = 6,566; 0.86 (0.78-0.94).

24 r undergoing an immunological test for fecal occult blood or colonoscopy.

25 etter screening compliance compared to fecal occult blood or endoscopic screening.

26 sment when interpreting sensitivity of fecal occult blood or other screening tests derived from studi

27 1.439-1.875; p < 0.001), and positive stool occult blood (OR, 1.829; CI, 1.545-2.167; p < 0.001).

28 pg/ml (odds ratio [OR]: 7.3), positive fecal occult blood (OR: 13.2), hemoglobin < or =90 g/l (OR: 6.

29 tion of hematochezia (19%) or positive fecal occult blood test (15%).

30 ry care providers use only the digital fecal occult blood test (FOBT) as their primary screening test

31 screened, the use of high-sensitivity fecal occult blood test (FOBT) decreased between 2011 and 2019

32 ing test for colorectal neoplasia; the fecal occult blood test (FOBT) detects neoplasias with low lev

33 y compared three screening modalities: Fecal Occult Blood Test (FOBT) followed by colonoscopy or sigm

34 The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) scr

35 as average risk, suggesting the use of fecal occult blood test (FOBT) instead of colonoscopy.

36 The Fecal Occult Blood Test (FOBT) is one of the diagnostic modali

37 ns age 50 to 75 years with an abnormal fecal occult blood test (FOBT) or fecal immunochemical test (F

38 Annual or biennial guaiac fecal occult blood test (gFOBT) vs no screening (5 trials, n =

39 1.38; 95% CI: 1.31, 1.45) but not with fecal occult blood test (HR, 1.00; 95% CI: 0.91, 1.10) than th

40 165.19), or having undergone a recent fecal occult blood test (OR, 13.69; 95% CI: 3.66, 51.29).

41 reening, 2) FIT: annual immunochemical fecal occult blood test age 40-75 years, 3) gFOBT: annual guai

42 5 years, 3) gFOBT: annual guaiac-based fecal occult blood test age 40-75 years, and 4) COL: 10-yearly

43 ical smear test, 2) a mammogram, 3) a faecal occult blood test and 4) a prostate specific antigen tes

44 erred for colonoscopy with a positive faecal occult blood test as part of the UK national bowel cance

45 rs (for example, simplifying access to fecal occult blood test cards), or made system-level changes (

46 anol, RNAlater Stabilization Solution, fecal occult blood test cards, and fecal immunochemical test t

47 The stool occult blood test continues to be utilized for reasons o

48 The Se of the occult blood test for CRC detection was calculated to be

49 tal tests was defined by a record of a fecal occult blood test in the past 2 years, flexible sigmoido

50 early cancer include sensitive guaiac fecal occult blood test or fecal immunochemical test.

51 Consecutive patients with a positive faecal occult blood test or previous adenomas undergoing survei

52 agnostic indications, such as positive fecal occult blood test result (OR, 0.33; 95% CI, 0.19-0.57),

53 ies, these guidelines recommend annual fecal occult blood test screening plus periodic flexible sigmo

54 assing the first screening round of a faecal occult blood test screening programme in a single geogra

55 persons who have positive results on a fecal occult blood test should have a full colonic examination

56 lonoscopy, flexible sigmoidoscopy, and fecal occult blood test were 27.9, 0.6, and 29.5 per 1000 pers

57 colorectal cancer (CRC) by the guaiac fecal occult blood test, interval cancers develop in 48% to 55

58 ography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the mu

59 the sensitivity and specificity of the fecal occult blood test.

60 o screening with biennial guaiac-based fecal occult blood test.

61 onoscopy, serum CEA, punch biopsy and Faecal occult blood test.

62 Combined one-time screening with a fecal occult-blood test and sigmoidoscopy identified 75.8 perc

63 in stool samples with the Hemoccult II fecal occult-blood test in average-risk, asymptomatic persons

64 nsitivity of one-time screening with a fecal occult-blood test plus sigmoidoscopy.

65 One-time screening with both a fecal occult-blood test with rehydration and sigmoidoscopy fai

66 40%), blood glucose measurement (41%), fecal occult blood testing (39%), and chest radiography (36%),

67 creening by fecal DNA testing (F-DNA), fecal occult blood testing (FOBT) and/or sigmoidoscopy, or col

68 d mammography, Papanicolaou tests, and fecal occult blood testing (FOBT) but not colonoscopy, flexibl

69 per year of life saved), using annual fecal occult blood testing (FOBT) combined with flexible sigmo

70 lonoscopy or sigmoidoscopy (year 1) or fecal occult blood testing (FOBT) in year 1 and FOBT, colonosc

71 opy plus either sensitive unrehydrated fecal occult blood testing (FOBT) or fecal immunochemical test

72 gy for white men was annual rehydrated fecal occult blood testing (FOBT) plus sigmoidoscopy (followed

73 ikely to have negative attitudes about fecal occult blood testing (FOBT), but not about flexible sigm

74 f once-only flexible sigmoidoscopy and fecal occult blood testing (FOBT).

75 years, annual highly sensitive guaiac fecal occult blood testing (HSFOBT), annual fecal immunochemic

76 f biennial screening with guaiac-based fecal occult blood testing (n = 419,966) showed reduced CRC-sp

77 Screening Programme (asymptomatic but faecal occult blood testing [FOBt] positive).

78 the results of tests for inflammation (stool occult blood testing [Hemoccult], fecal leukocytes, feca

79 ded to improve patient compliance with fecal occult blood testing and colorectal cancer screening in

80 d clinical trials to reduce mortality: fecal occult blood testing and flexible sigmoidoscopy.

81 Combining fecal occult blood testing and sigmoidoscopy may decrease mort

82 s likely than nonphysicians to undergo fecal occult blood testing and were more likely to undergo col

83 sting or high-sensitivity guaiac-based fecal occult blood testing every 2 years, colonoscopy every 10

84 d with sigmoidoscopy every 5 years and fecal occult blood testing every year (FS/FOBT) or colonoscopy

85 creened population within 1 year using fecal occult blood testing followed by diagnostic colonoscopy

86 cohort study of routine screening with fecal occult blood testing found a 14% decrease in CRC mortali

87 on screening every 3 years plus annual fecal occult blood testing had an ICER of more than $100,000 p

88 istory of colon cancer and had not had fecal occult blood testing in the past year or flexible sigmoi

89 Fecal occult blood testing is a popular screening test because

90 If occult blood testing is done, clinicians must decide how

91 positives and high false negatives of fecal occult blood testing lead to high costs and low cost-eff

92 cancer was detected by screening using fecal occult blood testing or evaluation of symptoms.

93 Fecal occult blood testing or flexible sigmoidoscopy was order

94 diagnostic yield supported the use of fecal occult blood testing plus sigmoidoscopy.

95 55 years in addition to the biennial faecal occult blood testing programme offered to all individual

96 t age 65) or the combination of annual fecal occult blood testing with sigmoidoscopy every 5 years ar

97 reasonable substitutes for traditional fecal occult blood testing, although modeling may be needed to

98 ed trials support the use of screening fecal occult blood testing, and case-control studies support t

99 Screening with sensitive guaiac-based fecal occult blood testing, fecal immunochemical testing (FIT)

100 favorably with reported performance of fecal occult blood testing, flexible sigmoidoscopy, and barium

101 3 years, or every 5 years with annual fecal occult blood testing, had an ICER of less than $55,600 p

102 g have illustrated efficacy, including fecal occult blood testing, sigmoidoscopy and colonoscopy.

103 underwent comprehensive screening with stool occult blood testing, standard upper gastrointestinal en

104 elevant to optimizing the technique of fecal occult blood testing.

105 ears to be lower than that with guaiac fecal occult blood testing.

106 aou smears, cholesterol screening, and fecal occult blood testing.

107 y exists for widespread screening with fecal occult blood testing.

108 Fecal occult-blood testing and sigmoidoscopy have been recomme

109 returned the three specimen cards for fecal occult-blood testing and underwent a complete colonoscop

110 Although fecal occult-blood testing is the only available noninvasive s

111 The effect of screening with fecal occult-blood testing on colorectal-cancer mortality pers

112 In randomized trials, fecal occult-blood testing reduces mortality from colorectal c

113 The use of either annual or biennial fecal occult-blood testing significantly reduces the incidence

114 cards from three consecutive days for fecal occult-blood testing, which were rehydrated for interpre

115 r to annual or biennial screening with fecal occult-blood testing.

116 orectal cancer by use of guaiac-based faecal occult blood tests (FOBT) reduces disease-specific morta

117 Rates of patient completion of fecal occult blood tests (FOBTs) are often low.

118 Consecutive rounds of fecal occult blood tests (FOBTs) are used to screen for colore

119 Fecal occult blood tests (FOBTs), flexible sigmoidoscopy, or c

120 confidence interval (CI): 1.17, 2.19), fecal occult blood tests (HR=1.31, 95% CI: 1.12, 1.53), screen

121 ained fecal suspensions were used to perform occult blood tests for GI cancer screening and for micro

122 When used for screening, fecal occult blood tests have positive results about 1% to 16%

123 Screening for colorectal cancer with fecal occult blood tests or sigmoidoscopy can reduce mortality

124 ices Task Force endorse screening with fecal occult blood tests or sigmoidoscopy.

125 , with less invasive tests (sigmoidoscopy or occult blood tests) for lower-risk persons and colonosco

126 78 healthy women aged 70-74 years with fecal occult blood tests, 431 women aged 75-79 years in poor h

127 alth status using 3 strategies: annual fecal occult blood tests, flexible sigmoidoscopy every 5 years

128 nformation that can be used to perform fecal occult blood tests, interpret the results of those tests

129 A number of screening tests, including fecal occult blood tests, sigmoidoscopy, double-contrast bariu

130 etter performance characteristics than fecal occult blood tests.

131 ged 80-84 years in average health with fecal occult blood tests.

132 nal bleeding, as evidenced by positive fecal occult blood tests.

133 ge-matched men and women with negative fecal occult-blood tests and no family history of colon cancer

134 In a group of patients with positive fecal occult-blood tests who were referred for further evaluat

135 se a positive reaction on guaiac-based fecal occult-blood tests, the relative frequency of upper gast

136 A set of three fecal occult-blood tests--Hemoccult II; Hemoccult II Sensa, a

137 h subjects who had a negative test for fecal occult blood, the relative risk of advanced neoplasia in

138 Fecal occult blood was detected by standard guaiac-based tests

139 at least one stool specimen containing fecal occult blood who were referred for further evaluation.

140 Of the 409 patients with fecal occult blood who were referred, 310 were potentially eli